The 10 Tirzepatide Questions People Actually Ask, Answered From the Trials

Last verified November 2026 · 10 questions · 12 PubMed citations

Questions taken from r/tirzepatidecompound, r/Zepbound, r/Mounjaro

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

These questions come from patient forums, not from us, so they are what people want to know, phrased the way they ask it. Each answer is built from peer-reviewed trial data and the FDA label and links to the papers it rests on; the full reference list is at the foot of the page. Where a trial cannot answer the question, we say so.

Questions and answers

Q1.Does the weight return after stopping?

Most of it, and one trial was built specifically to measure that. SURMOUNT-4 enrolled people who had already lost about 20.9% over 36 weeks, then either kept them on the drug or moved them to placebo. The continuing group lost a further 5.5%, ending near 25% down; the placebo group regained about 14%, finishing roughly 9.9% below their starting weight. In that respect it works like a blood-pressure drug, with a benefit that lasts as long as you keep taking it. Expect some regain unless the changes to eating, activity and sleep hold on their own. Tapering was never tested, so if cost or supply is about to force a stop, raise it with whoever prescribes for you ahead of time rather than deciding it on a Sunday night.

Source thread ↗PMID 38078870 ↗

Q2.Does it stop working after a while?

No, but the scale will slow, and the reason is arithmetic rather than tolerance. SURMOUNT-1 showed the steepest loss in the first six to nine months, then a gentler slope, finishing near 20.9% at 72 weeks. People who stayed on the drug for a second year in SURMOUNT-4 lost another 5.5%, so the effect clearly does not switch off at one year. What changes is you: a smaller body burns fewer calories, so the same appetite reduction produces a smaller weekly deficit. If the scale stalls around month 14, the likely reason is that you are smaller now, not that the drug has failed. If weight has held steady for eight to twelve weeks at the highest dose you tolerate, raise it with your prescriber. A higher dose, more time, or resistance training are the levers, in roughly that order.

Source thread ↗PMID 35658024 ↗PMID 38078870 ↗

Q3.Has the appetite suppression stopped, or is my body fighting back?

Usually the second, and the distinction is testable. The drug reaches steady levels after about four weeks at a given dose and holds them, and no trial has shown it losing its grip on hunger at a stable dose. What does change is your metabolism: as weight falls, resting energy expenditure falls with it, hunger hormones rise, and the same dose is now working on a smaller person. SURMOUNT-1's curve flattened after roughly 60 weeks with everyone still on full dose, which is what adaptation looks like. As a practical check, if hunger has clearly risen over the last month or two at an unchanged dose, raise it with your prescriber. If hunger feels the same and only the scale has slowed, nothing has gone wrong.

Source thread ↗PMID 35658024 ↗PMID 37285081 ↗

Q4.Does the nausea get better, or should I quit?

For most people it eases. Nausea, diarrhea and constipation cluster around dose increases, run mild to moderate, and settle once you hold at a level. Discontinuation for side effects ran between 4% and 7% in the main trials against 2-3% on placebo, so the large majority finished. The four-week-per-step schedule exists to limit exactly this, and asking to stay an extra month on a step that felt rough is a normal request. Some symptoms should not be waited out: severe persistent stomach pain, repeated vomiting with dehydration, gallbladder symptoms, or hypoglycemia in anyone also taking insulin or a sulfonylurea. Those warrant a same-day call. Nausea that fades a little each week is the ordinary path.

Source thread ↗PMID 39789843 ↗PMID 35658024 ↗

Q5.Should I go up a dose or hold?

The trial data supports either, depending on what you are optimizing for. SURMOUNT-1 measured all three maintenance doses: 5 mg produced 15.0%, 10 mg produced 19.5%, and 15 mg produced 20.9%. More drug meant more weight lost and more stomach trouble, which is why the label climbs slowly. If you are still losing at a reasonable rate and tolerating it, many clinicians will hold; there is no prize for reaching the ceiling. If the scale has been flat two to three months at the highest dose you can handle and you have further to go, that is the usual cue to discuss a step. No trial has compared holding against escalating, so this one comes down to the individual. Side effects from a step tend to peak in the first week or two.

Source thread ↗PMID 35658024 ↗

Q6.Does it do anything besides weight?

Quite a lot, and each benefit has its own trial. SURMOUNT-OSA cut breathing interruptions by about 25 to 29 an hour in people with moderate-to-severe sleep apnea (roughly halving them), and tirzepatide became the first drug ever approved for that condition. SYNERGY-NASH resolved liver inflammation on biopsy in 44-62% against 10% on placebo. SUMMIT reduced the combined risk of cardiovascular death or worsening heart failure in people with obesity and the stiff-heart form of heart failure. SURPASS-2 dropped blood sugar 2.0-2.3 points in type 2 diabetes. And a long-term analysis found far fewer people with prediabetes progressed to diabetes. Blood pressure and lipids commonly improve too, though the trials were not built to prove those secondary findings.

Source thread ↗PMID 38912654 ↗PMID 38856224 ↗PMID 39555826 ↗PMID 34170647 ↗PMID 39536238 ↗

Q7.How does it compare with semaglutide?

This has been tested head to head. SURMOUNT-5 ran the two against each other for 72 weeks at the highest dose each person could tolerate: 20.2% against 13.7%, a gap of 6.5 percentage points. In diabetes, SURPASS-2 found the same direction on both blood sugar and weight. Both act on the GLP-1 receptor; tirzepatide adds a second, GIP, and that is the leading explanation for the gap. Those are averages, and individual responses vary enormously; in practice the outcome depends on which drug you can tolerate, afford and get covered. Switching between them happens routinely in clinics, though no trial has studied it.

Source thread ↗PMID 40353578 ↗PMID 34170647 ↗

Q8.Does it work through perimenopause, or alongside HRT?

Yes to both, with one caveat that has nothing to do with HRT. Women made up about 67% of SURMOUNT-1, and nothing published suggests that hormone therapy and tirzepatide interfere with each other. The interaction that matters is with the contraceptive pill. This drug slows gastric emptying, which can cut absorption of an oral estrogen. Per the label, oral contraceptives may lose effectiveness for four weeks after you start and for four weeks after each dose increase, and a barrier or non-oral method is advised across those windows. The warning names pills specifically. A patch or gel does not pass through the stomach, so it is not expected to be affected.

Source thread ↗PMID 35658024 ↗

Q9.Why am I starving by day 6?

Because the drug is wearing off, and that is expected. Its half-life runs about five days, so blood levels peak in the first one to three days and drift down toward the end of the week until the next injection lifts them again. Appetite follows that curve. Roughly four weeks of holding one dose brings you to steady state and narrows the swing, but a mild rise in hunger at the end of the week is normal and is not a sign it has quit working. The patterns people settle into: keep the injection on a fixed day, have higher-protein and higher-fiber food ready for the back half of the week, and do not plan to rely on willpower on day six. If the surges are big enough to undo your progress, raise it with your prescriber, and do not shorten the gap between injections on your own.

Source thread ↗PMID 37285081 ↗

Q10.Will I lose muscle?

Some, and mostly fat. A body-composition substudy of SURMOUNT-1 found that among people who lost about 21% of their body weight, roughly 75% of the loss was fat and 25% lean tissue. That split is close to what dieting alone produces, and because so much fat came off, the overall ratio of fat to lean tissue improved. It is an average. Too little protein, no resistance training, or losing very fast all push the lean share up. The countermeasures are cheap and well evidenced: protein at roughly 1.2-1.6 g per kg of body weight a day, resistance work two or three times a week, and no long stretches of very low intake.

Source thread ↗PMID 39996356 ↗PMID 40445127 ↗

References

  1. 1.Jastreboff AM, Aronne LJ, Ahmad NN, et al Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.
  2. 2.Aronne LJ, Horn DB, le Roux CW, et al Tirzepatide as Compared with Semaglutide for the Treatment of Obesity N Engl J Med. 2025. PMID: 40353578.
  3. 3.Malhotra A, Grunstein RR, Fietze I, et al Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity N Engl J Med. 2024. PMID: 38912654.
  4. 4.Frias JP, Davies MJ, Rosenstock J, et al Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes N Engl J Med. 2021. PMID: 34170647.
  5. 5.Loomba R, Hartman ML, Lawitz EJ, et al Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis N Engl J Med. 2024. PMID: 38856224.
  6. 6.Aronne LJ, Sattar N, Horn DB, et al Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. 2024. PMID: 38078870.
  7. 7.Jastreboff AM, le Roux CW, Stefanski A, et al Tirzepatide for Obesity Treatment and Diabetes Prevention N Engl J Med. 2025. PMID: 39536238.
  8. 8.Rubino DM, Pedersen SD, Connery L, et al Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT trials Diabetes Obes Metab. 2025. PMID: 39789843.
  9. 9.Look M, Dunn JP, Kushner RF, et al Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Diabetes Obes Metab. 2025. PMID: 39996356.
  10. 10.Packer M, Zile MR, Kramer CM, et al Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity N Engl J Med. 2025. PMID: 39555826.
  11. 11.Feng P, Sheng X, Ji Y, et al A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes Adv Ther. 2023. PMID: 37285081.
  12. 12.Mozaffarian D, Agarwal M, Aggarwal M, et al Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society Obesity (Silver Spring). 2025. PMID: 40445127.

Questions are paraphrased from public forum threads and linked to their source where one was recorded. Answers summarize published trial data and FDA labeling. This is not medical advice, and no part of it replaces the judgment of whoever prescribes for you.